Adult acute lymphoblastic leukemia (ALL) is a sig-nificantly different disease when compared to childhood acute lymphoblastic leukemia. In adults it is basically a dis-ease of early adulthood with a higher incidence in males. Etiology as with most other cancers is unknown. However, certain factors are important that include hereditary disor-ders, high socioeconomic status and radiation exposure.1 Like childhood ALL, adult ALL also comprises of B and T phenotype2, however with the introduction of more inten-sive therapeutic protocols, there is no difference in these two subtypes as far as the long term prognosis is concerned which was previously poor for T ALL. The main biological difference is presence of Philadelphia chromosome seen only i...
Lymphoblastic leukemia/lymphoblastic lymphomarepresents a heterogeneous group of neoplasmsarising fr...
Acute lymphoblastic leukemia (ALL) represents a biologically and clinically heterogeneous group of d...
Pretreatment cytogenetics is a known predictor of outcome in hematologic malignancies. However, its ...
Acute lymphoblastic leukemia (ALL) in adults is a rare malignancy. It represents 1-2% of all cancers...
This paper analyzes the difference between Acute Lymphoblastic Leukemia (ALL) in adults and children...
Acute lymphoblastic leukemia (ALL) in adults is a rare malignancy. It represents 1-2 % of all can-ce...
Acute lymphoblastic leukaemia (ALL) is a disease diagnosed in children as well as adults. Progress i...
Acute lymphoblastic leukaemia (ALL) is a disease diagnosed in children as well as adults. Progress i...
Acute lymphoblastic leukemia (ALL) is the most frequent neoplastic disease in children, being a rare...
It is a new and exciting time for acute lymphoblastic leukemia (ALL). While nearly 50 years ago, onl...
With intensified pediatric-like therapy and genetic disease dissection, the field of adult acute lym...
T cell acute lymphoblastic leukemia (T-ALL) is a heterogeneous disease in which genetic lesions coor...
Acute lymphoblastic leukemia (ALL) is classified as B-lineage ALL (B-ALL) and T-lineage ALL (T-ALL)....
recent study from the German Multi-center acute lymphoblastic leukemia (GMALL) Group reported state-...
This review focuses on the most recent advances in the diagnostic and prognostic work-up of adult ac...
Lymphoblastic leukemia/lymphoblastic lymphomarepresents a heterogeneous group of neoplasmsarising fr...
Acute lymphoblastic leukemia (ALL) represents a biologically and clinically heterogeneous group of d...
Pretreatment cytogenetics is a known predictor of outcome in hematologic malignancies. However, its ...
Acute lymphoblastic leukemia (ALL) in adults is a rare malignancy. It represents 1-2% of all cancers...
This paper analyzes the difference between Acute Lymphoblastic Leukemia (ALL) in adults and children...
Acute lymphoblastic leukemia (ALL) in adults is a rare malignancy. It represents 1-2 % of all can-ce...
Acute lymphoblastic leukaemia (ALL) is a disease diagnosed in children as well as adults. Progress i...
Acute lymphoblastic leukaemia (ALL) is a disease diagnosed in children as well as adults. Progress i...
Acute lymphoblastic leukemia (ALL) is the most frequent neoplastic disease in children, being a rare...
It is a new and exciting time for acute lymphoblastic leukemia (ALL). While nearly 50 years ago, onl...
With intensified pediatric-like therapy and genetic disease dissection, the field of adult acute lym...
T cell acute lymphoblastic leukemia (T-ALL) is a heterogeneous disease in which genetic lesions coor...
Acute lymphoblastic leukemia (ALL) is classified as B-lineage ALL (B-ALL) and T-lineage ALL (T-ALL)....
recent study from the German Multi-center acute lymphoblastic leukemia (GMALL) Group reported state-...
This review focuses on the most recent advances in the diagnostic and prognostic work-up of adult ac...
Lymphoblastic leukemia/lymphoblastic lymphomarepresents a heterogeneous group of neoplasmsarising fr...
Acute lymphoblastic leukemia (ALL) represents a biologically and clinically heterogeneous group of d...
Pretreatment cytogenetics is a known predictor of outcome in hematologic malignancies. However, its ...